Change in the number of votes relating to Biotie Therapies Corp.'s shares

Wed Sep 4, 2013 4:00am EDT

* Reuters is not responsible for the content in this press release.

Biotie Therapies Corp.          Stock Exchange Release    4 September 2013 at 11.00 a.m.

Change in the number of votes relating to Biotie Therapies Corp.'s shares

The Swiss subsidiary of Biotie Therapies Corp. ("Biotie" or the "Company"), Biotie Therapies AG (previously Synosia Therapeutics Holding AG and Biotie Therapies Holding AG) has conveyed Biotie shares against consideration pursuant to the option programs as follows:

August 2013 Total
% of the total
amount of
1,306,797   8,192,260 6,327,235 1.4%

The conveyance of Biotie shares relates to the option plan of Synosia Therapeutics Holding AG (currently Biotie Therapies Holding AG, "Synosia") acquired by Biotie in February 2011. According to such Synosia share option plan, options have been granted to employees, former directors and consultants. In connection with the completion of the acquisition of Synosia, the option plan was amended so that instead of shares in Synosia an aggregate maximum of 14,912,155 shares in Biotie may be subscribed based on the plan. Biotie issued these 14,912,155 shares to its current subsidiary Synosia in connection with the acquisition to be further conveyed to the option holders when they potentially exercise their option rights in accordance with the terms and conditions of the option program.

The conveyed shares previously held by the Company's subsidiary have not carried any voting rights. The parent company Biotie does not own any treasury shares. The conveyance does not affect the number of registered shares.

After the conveyances the changes are as follows:

The increase of vote of the Company
August 2013
A total amount of
voting rights:
The number of the
Company's share held
by the Group
August 2013
The total number
of registered
1,306,797        445,990,843              6,719,895 452,710,738

Turku, 4 September 2013

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900

NASDAQ OMX Helsinki Ltd
Main Media  

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Biotie Therapies Oyj via Thomson Reuters ONE